Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR-BLEED-2: Switching From Clopidogrel to Low-dose Prasugrel in Dual-risk Patients Following PCI
NCT07025148Phase 4Recruiting
- Sponsor
- University of Florida
- Start
- Oct 2025
- Primary completion
- Aug 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel in coronary artery disease (CAD) (3 arms), sponsored by University of Florida. Primary endpoint: Platelet Reactivity Units at 30 days. Started Oct 2025; status: recruiting.
02
Drugs
prasugrel
03
Conditions
coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT07025148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07025148.